Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis

Ting CY 1 , Liew SM 2 , Price A 3 , Gan GG 1 , Bee-Lan Ong D 4 , Tan SY 5 Show all authors , Bee PC 6

Affiliations 

  • 1 Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia
  • 2 Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Malaysia
  • 3 University of Oxford, Centre for Evidence Based Medicine, England, United Kingdom
  • 4 Department of Pathology, Faculty of Medicine, University of Malaya, Malaysia
  • 5 Department of Pathology, National University of Singapore, Singapore
  • 6 Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia. Electronic address: pcbee@um.edu.my
Crit Rev Oncol Hematol, 2019 Dec;144:102818.
PMID: 31733445 DOI: 10.1016/j.critrevonc.2019.102818

Abstract

The clinical significance of aberrantly expressed microRNAs in predicting treatment response to chemotherapy in diffuse large B-cell lymphoma patients (DLBCL) remains uncertain. Feasibility of microRNA testing to predict treatment outcome was evaluated. Twenty-two types of aberrantly expressed microRNAs were associated with poor treatment response; pooled hazard ratio (HR) was 2.14 [95%CI:1.78-2.57, P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications